drugset / Trial / NCT05471700

Single Arm Study of Azacitidine and Venetoclax for Treatment of Newly Diagnosed Fit Acute Myeloid Leukemia Patients

NCT05471700

Completed 40 enrolled Zhujiang Hospital
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to evaluate the safety and efficacy of Azacytidine in combination with Venetoclax in patients with newly diagnosed fit acute myeloid leukemia.

Timeline

Start
2022-09-01
Primary completion
2023-04-04
Completion
2023-04-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Azacitidine Other / unclassified 75 mg/m2 Subcutaneous
Subject Venetoclax Small molecule 400 mg Oral